Telehealth company Hims & Hers Health (NYSE:HIMS) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 72.6% year on year to $544.8 million. On the other hand, the company expects next quarter’s revenue to be around $580 million, close to analysts’ estimates. Its GAAP profit of $0.17 per share was 13% above analysts’ consensus estimates.
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
Wall Street has issued downbeat forecasts for the stocks in this article.
These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Shares of telehealth company Hims & Hers Health are up Thursday afternoon. The rally comes amid significant headwinds for major pharmaceutical companies in the lucrative weight-loss drug market.
HIMS & HERS HEALTH INC (NYSE:HIMS) excels in both technical momentum and high-growth fundamentals, fitting Mark Minervini’s trend strategy with strong earnings, revenue growth, and rising stock trends.
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and a look at the reasons why and what's next.
